WE CLAIM:

1. Use of D-cycloserine (DCS) in the manufacture of a medicament to augment transcranial magnetic stimulation (TMS) therapy for Major Depressive Disorder (MDD) optionally intermittent or continuous theta-burst stimulation (iTBS or cTBS), high- or low-frequency stimulation and combinations thereof, to improve depressive symptoms and provide higher rates of clinical response and remission.
2. Use of D-cycloserine in the manufacture of a medicament in combination with transcranial magnetic stimulation to treat Major Depressive Disorder (MDD) in a patient and/or improve and/or alleviate and/or reduce frequency of one or more symptoms of MDD, wherein the D-cycloserine is for administration to the patient at a dose of 1-250mg; and wherein the transcranial magnetic stimulation is optionally intermittent or continuous theta-burst stimulation (iTBS or cTBS), high- or low-frequency stimulation or combinations thereof.
3. The use of claim 2, wherein the one or more symptoms of MDD include feelings of sadness, tearfulness, hopelessness, short temper, irritability, loss of interest/lack of pleasure, concentration impairments, indecision, memory loss, flat affect, sleep disorders, tiredness, reduced or increased appetite, weight loss or weight gain, feelings of worthlessness or guilt, thoughts of death and/or suicide.
4. Use of low-dose D-cycloserine with transcranial magnetic stimulation in the manufacture of a medicament for the management of Major Depressive Disorder (MDD), wherein the low dose is a dose of D-cycloserine sufficient to achieve a plasma concentration of D-cycloserine of 1-30 µg/mL.
5. The use of claim 2, wherein the dose is a dose of D-cycloserine sufficient to achieve a plasma concentration of D-cycloserine of 1-30 µg/mL.
6. Use of D-cycloserine in the manufacture of a medicament for improving and/or reversing and/or partially reversing cognitive impairments in MDD, including working memory and overall subjective cognitive function, wherein the medicament is for administration to the patient at a dose of 1-250 mg; and wherein the patient is subject to transcranial magnetic stimulation, optionally intermittent or continuous theta-burst stimulation (iTBS or cTBS), high- or low-frequency stimulation or combinations thereof.
7. The use according to claim 6, wherein the dose is a dose of D-cycloserine sufficient to achieve a plasma concentration of D-cycloserine of 1-30 µg/mL.
8. Use of D-cycloserine in the manufacture of a medicament to reduce suicide risk and suicidal ideation in MDD, wherein the medicament is for administration to a patient at a dose of 1-250 mag; and wherein the patient is subject to transcranial magnetic

stimulation, optionally intermittent or continuous theta-burst stimulation (iTBS or cTBS), high- or low-frequency stimulation or combinations thereof.

9. The use according to claim 9, wherein the low dose is a dose of D-cycloserine sufficient to achieve a plasma concentration of D-cycloserine of 1-30 μg/mL.
10. Use of D-cycloserine in the manufacture of a medicament to improve anxiety symptoms associated with MDD, wherein the medicament is for administration to the patient at a dose of 1-250 mg per patient; and wherein the patient is subject to transcranial magnetic stimulation, optionally intermittent or continuous theta-burst stimulation (iTBS or cTBS), high- or low-frequency stimulation or combinations thereof.
11. The use according to claim 10, wherein the dose is a dose of D-cycloserine sufficient to achieve a plasma concentration of D-cycloserine of 1-30 μg/mL.
12. Use of D-cycloserine in the manufacture of a medicament to prolong effects of transcranial magnetic stimulation, including intermittent theta-burst stimulation, as measured by neurophysiology including electromyography or encephalography, wherein the medicament is for administration to the patient a dose of 1-250 mg per patient and wherein the patient is subject to transcranial magnetic stimulation, optionally intermittent or continuous theta-burst stimulation (iTBS or cTBS), high- or low-frequency stimulation or combinations thereof.